Analysis of complex protein-protein-interactions made easy

ChromoTek’s fluorescent two hybrid (F2H®) technology enables screening and validation of compounds in living cells

ChromoTek Logo
(PresseBox) ( Planegg-Martinsried, )
ChromoTek GmbH (Munich, Germany) has developed a series of highly sensitive protein-protein-interaction (PPI) assays to screen compounds that resolve the binding of two proteins within cells. The so-called fluorescent two hybrid (F2H®) technology is based on a proprietary cell line that contains a spot-like landing platform where one interaction partner binds. The interacting proteins are tagged with different fluorescent proteins and co-localize to the same spot upon binding. The resulting bright dual fluorescent merge signal is clearly detectable and measurable under the microscope. Disruption of the binding by test substances recreates a single fluorescent spot. For drug discovery campaigns the F2H® platform can be fully automated.

One particular advantage of the F2H® platform is that only those molecules will emerge as possible drug candidates which are taken up into cells and which show little or no cytotoxicity. In addition, due to the standardized binding platform used, it is possible to conduct comparative protein-protein-interaction (PPI) studies.

To date, more than 50 protein-protein-interactions have been successfully reconstructed with the F2H® system. "For example, by tracing the binding of p53 to Mdm2 or Mdm4, known inhibitors of these interactions could be verified and new inhibitors identified" states Dr. Kourosh Zolghadr, Head of R&D at ChromoTek. ChromoTek's academic partner, Prof. Sir David Lane, calls the F2H® approach a missing link between biochemistry and cell biology. In collaboration with his lab, the F2H® assay was successfully applied for comprehensive (stapled) peptide profiling for activation of p53 (recently published in ACS Chem. Biol. 8 (3): 506-512 (2013)).

ChromoTek not only offers p53:Mdm2 and/or p53:Mdm4 compound screening and profiling services but, owing to the flexibility and versatility of this new technology, develops customized F2H® PPI assays to conduct compound screening services for biotech/pharma partners aiming to increase the efficiency of their drug discovery and validation programs with real time cellular data.
Für die oben stehenden Pressemitteilungen, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Meldungstitel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Pressetexte sowie der angehängten Bild-, Ton- und Informationsmaterialien.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an